Study of Circadian Clock Properties in Healthy Subjects, Obese and Type 2 Diabetic Patients.
This trial is active, not recruiting.
|Conditions||circadian rhythm, diabetes, obesity|
|Treatments||circadian rhythm measurement, skin biopsy|
|Sponsor||University Hospital, Geneva|
|Start date||June 2011|
|End date||December 2017|
|Trial size||300 participants|
|Trial identifier||NCT02384148, 11-015|
The investigators aimed to characterize human circadian clockwork in healthy individuals in comparison to obese and type 2 diabetic subjects, employing the noninvasive experimental approach allowing the study of circadian profile in human individuals.
Difference of period length
time frame: 5 days
Difference of amplitude
time frame: 5 days
Male or female participants from 20 years up to 80 years old.
Inclusion Criteria: - age 20-80 - consent obtained Exclusion Criteria: - neoplasia - inflammatory disease - allergy to lidocaine
|Official title||Measure and Comparison of Molecular Circadian Clock Properties in Healthy Subjects, Obese and Type 2 Diabetic Patients.|
|Description||The investigators specifically aim to obtain and analyze the circadian profile of skin fibroblasts from healthy, obese and T2D subjects. Does circadian oscillator profile and its parameters (phase, period and amplitude) will differ between healthy individuals and obese/ T2D patients? Skin biopsy will be performed in order to collect and culture skin fibroblast cells. In vivo bioluminescence recording will be performed in primary human skin fibroblast cells. The profiles obtained from 10 subjects in each group will be compared to their healthy counterparts. Bmal1and Per2 are clock genes. Lentiviral transduction of Bmal1-luciferase or Per2-luciferase in fibroblasts allow observation of circadian oscillations using bioluminescence assay. Phase, period length and amplitude are used to characterize the circadian rhythm.|
Call for more information